Tuğba GÜRPINAR, NURAN EKERBİÇER, Nazan UYSAL, Turgay BARUT, Figen TARAKÇI, M. İbrahim TUĞLU

The histologic evaluation of atorvastatin and melatonin treatment on oxidative stress and apoptosis of diabetic rat pancreas

Diyabette reaktif oksijen bileşiklerinin aşırı üretimi ve nitrik oksidin azalmış biyoyararlanımına bağlı olarak oksidatif stres artmaktadır. Antioksidan tedavi diyabette oksidatif hasarı önlemek için kullanılmaktadır. Bu araştırmanın amacı, atorvastatin (AT) ve melatonin (MLT) tedavisinin oksidatif stres üzerine etkilerini diabetik sıçan pankreasında araştırmak, nitrik oksid sentaz (NOS) aktivitesi ve apoptoz ile ilişkisini değerlendirmektir. Diyabet oluşumu tek doz streptozotozin (STZ, 55 mg/kg, IP) ile indüklendi. 6 hafta sonra sıçanlar 5 gruba ayrıldı. AT uygulanan diyabetik grup (STZ+AT), MLT uygulanan diyabetik grup (STZ+MLT), AT ve MLT uygulanan diyabetik grup (STZ+AT+MLT). Kontrol ve diyabetik kontrol grupları da oluşturulmuştur. AT 8 mg/kg oral yoldan uygulanmış, MLT ise 10 mg/kg/gün olarak 6. haftadan başlayarak 2 hafta boyunca IP yolla uygulanmıştır. Pankreas dokusu immunohistokimyasal yöntemlerle incelenmiştir. Antioksidan durumla ilgili olarak belirgin bir farklılık gözlenmemekle birlikte, NOS aktivitesi tedavi almayan diyabetik sıçanlarda tedavi alan gruplara göre daha yüksek olma eğilimi gösterdi. AT ve MLT tedavisinin pankreasta histopatolojik olarak apoptosis ve oksidatif stresi de içeren iyileşmeye neden olduğu gösterildi.

Anahtar Kelimeler:

programlanmış hücre ölümü, biyoyararlanım, diyabet, ilaç tedavisi, histopatoloji, melatonin, nitrik oksit, oksitlenme, stres, sıçan, pankreas

Atorvastatin ve melatonin tedavisinin diyabetik sıçan pankreasında oksidatif stres ve apoptozise etkilerinin histolojik incelemesi

In the diabetic state, there is an enhanced oxidative stress due to excessive production of reactive oxygen compounds and decreased bioavailability of nitric oxide. Antioxidant treatment has been used to prevent oxidative damage in diabetes. The objective of the present study was to explore the effects of atorvastatin (AT) and melatonin (MLT) on oxidative stress in diabetic rat pancreas. We also assessed nitric oxide synthase (NOS) activity and apoptosis. Diabetes was induced by an alkylating agent steptozotocin (STZ, 55 mg/kg, IP). Six weeks later rats were divided into five groups: STZ-induced diabetic group received atorvastatin (STZ+AT), STZ-induced diabetic group received melatonin (STZ+MLT) and STZ-induced diabetic group received atorvastatin and melatonin (STZ+AT+MLT). The vehicle-treated non-diabetic (CT) and diabetic group (STZ-CT) served as normoglycemic and diabetic controls. AT was given 8 mg/kg orally and MLT was given 10 mg/kg/IP once a day for 2 weeks beginning from the sixth week. Pancreatic tissue was examined by immunohistochemical methods. Although no significant difference was observed with respect to antioxidant status, NOS activity was tended to be higher in the untreated diabetic rats than in the treated rats. We observed that AT and MLT treatment improved the histopathological changes including apoptosis and oxidative stress in diabetic pancreas.

Keywords:

apoptosis, bioavailability, diabetes, drug therapy, histopathology, melatonin, nitric oxide, oxidation, stress, rats, pancreas,

PDF

___

1. Schalkwijk CG, Stehouwer CD: Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond), 109 (2): 143-159, 2005.
2. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis, Physiol Rev, 84 (4): 1381-478, 2004.
3. Yamagishi N, Nakayama K, Wakatsuki T, Hatayama T: Characteristic changes of stress protein expression in streptozotocin -induced diabetic rats. Life Sci, 69, 2603-2609, 2001.
4. Yang H, Wright JR: Human beta cells are exceedingly resistant to streptozotocin in vivo. Endocrinology, 143, 24912495, 2002.
5. O’Brien BA, Harmon BV, Cameron DP, Allan DJ: Apoptosis is the mode of beta-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes, 46, 750-757, 1997.
6. Kajimoto Y, Kaneto H: Role of oxidative stress in pancreatic beta-cell dysfunction. Ann N Y Acad Sci, 1011, 168-176, 2004.
7. Kwon NS, Lee SH, Choi CS, Kho T, Lee HS: Nitric oxide generation from streptozotocin. FASEB J, 8, 529-536, 1994.
8. Kaneto H, Fujii J, Seo HG, Suzuki K, Matsuoka T, Nakamura M, Tatsumi H, Yamasaki Y, Kamada T, Taniguchi N: Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes, 44 (7): 733-738, 1995.
9. Saini KS, Thompson C, Winterford CM, Walker NI, Cameron DP: Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic beta cell line, INS1. Biochem Mol Biol Int, 39 (6): 1229-1236, 1996.
10. Siman CM, Eriksson UJ: Vitamin E decreases the occurrence of malformations in the offspring of diabetic rats. Diabetes, 46, 1054-1061, 1997.
11. Cam M, Yavuz O, Guven A, Ercan F, Bukan N, Ustündag N: Protective effects of chronic melatonin treatment against renal injury in streptozotocin-induced diabetic rats. J Pineal Res, 35, 212-220, 2003.
12. Vural H, Sabuncu T, Arslan SO, Aksoy N: Melatonin lipid peroxidation and stimulates the antioxidant diabetic rats. J Pineal Res, 31, 193-198, 2001.
13. Padillo FJ, Cruz A, Navarrete C, Bujalance I, Briceño J, Gallardo JI: Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radic Res, 38, 697-704, 2004.
14. Peschke E, Fauteck JD, Musshoff U, Schmidt F, Beckmann A, Peschke D: Evidence for a melatonin receptor within pancreatic islets of neonate rats: Functional, autoradiographic, and molecular investigations. J Pineal Res, 28 (3): 156-164, 2000.
15. Abdel-Wahab MH, Abd-Allah AR: Possible protective effect of melatonin and/or desferrioxamine against streptozotocin induced hyperglycaemia in mice. Pharmacol Res, 41 (5): 533537, 2000.
16. Peschke E: Melatonin, endocrine pancreas and diabetes. J Pineal Res, 44 (1): 26-40, 2008.
17. Yavuz O, Cam M, Bukan N, Guven A, Silan F: Protective effect of melatonin on beta-cell damage in streptozotocininduced diabetes in rats. Acta Histochem, 105 (3): 261-266, 2003.
18. Liao JK: Statins: Potent vascular anti-inflammatory agents. Int J Clin Pract Suppl, 143, 41-48, 2004.
19. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y: Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels, 20 (4): 133-136, 2005.
20. Shaw SM, Fildes JE, Yonan N, Williams SG: Pleiotropic effects and cholesterol-lowering therapy. Cardiology, 112 (1): 412, 2009.
21. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J: Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Curr Med Chem, 14 (2): 243-248, 2007.
22. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci, 95, 88808885, 1998.
23. Mäuser W, Perwitz N, Meier B, Fasshauer M, Klein J: Direct adipotropic actions of atorvastatin: differentiation state- dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol, 14, 564, 37-46, 2007.
24. González E, Roselló-Catafau J, Jawerbaum A, Sinner D, Pustovrh C, Vela J: Pancreatic nitric oxide and oxygen free radicals in the early stages of streptozotocin-induced diabetes mellitus in the rat. Braz J Med Biol Res, 33 (11): 1335-1342, 2000.
25. Tanaka Y, Shimizu H, Sato N, Mori M, Shimomura Y: Involvement of spontaneous nitric oxide production in the diabetogenic action of streptozotocin. Pharmacology, 50, 6974, 1995.
26. McDaniel M, Kwon G, Hill JR, Marshall C, Corbett J: Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med, 211, 24-32, 1996.
27. Delaney CA, Eizirik DL: Intracellular targets for nitric oxide toxicity to pancreatic beta-cells. Braz J Med Biol Res, 29 (5): 569-579, 1996.
28. Anwar MM, Meki AR: Oxidative stress in streptozotocininduced diabetic rats: effects of garlic oil and melatonin. Comp Biochem Physiol A Mol Integr Physiol, 135 (4): 539-547, 2003.
29. Kanter M, Uysal H, Karaca T, Sagmanligil HO: Depression of glucose levels and partial restoration of pancreatic beta-cell damage by melatonin in streptozotocin-induced diabetic rats. Arch Toxicol, 80 (6): 362-9, 2006
30. Kanda M, Satoh K, Ichihara K: Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull, 26 (12): 681-684, 2003.
31. Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, Ichihara K: HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull, 28 (11): 2092-2095, 2005.
32. Uzun M, Çitil M, Atakişi O, Uzlu E, Yapar K, Erdoğan HM: Plasma nitric oxide levels after injection of therapeutic dose of methylprednisolone acetate in rabbits. Kafkas Univ Vet Fak Derg, 14 (2): 169-172, 2008.